These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68 related articles for article (PubMed ID: 16417428)
1. Immunological responses and the pattern of disease in mice infected with transfected Leishmania major constitutively expressing active IL-1alpha. Bersudsky M; Laban A; El-On J Vector Borne Zoonotic Dis; 2005; 5(4):324-9. PubMed ID: 16417428 [TBL] [Abstract][Full Text] [Related]
2. Leishmania major: a clone with low virulence for BALB/c mice elicits a Th1 type response and protects against infection with a highly virulent clone. Li J; Nolan TJ; Farrell JP Exp Parasitol; 1997 Sep; 87(1):47-57. PubMed ID: 9287957 [TBL] [Abstract][Full Text] [Related]
3. Distinct roles for IL-1 receptor type I signaling in early versus established Leishmania major infections. Kostka SL; Knop J; Konur A; Udey MC; von Stebut E J Invest Dermatol; 2006 Jul; 126(7):1582-9. PubMed ID: 16645594 [TBL] [Abstract][Full Text] [Related]
4. A single intramuscular injection with an adenovirus-expressing IL-12 protects BALB/c mice against Leishmania major infection, while treatment with an IL-4-expressing vector increases disease susceptibility in B10.D2 mice. Gabaglia CR; Pedersen B; Hitt M; Burdin N; Sercarz EE; Graham FL; Gauldie J; Braciak TA J Immunol; 1999 Jan; 162(2):753-60. PubMed ID: 9916695 [TBL] [Abstract][Full Text] [Related]
6. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis. Webb JR; Kaufmann D; Campos-Neto A; Reed SG J Immunol; 1996 Dec; 157(11):5034-41. PubMed ID: 8943412 [TBL] [Abstract][Full Text] [Related]
7. Differential regulation of IL-9-expression after infection with Leishmania major in susceptible and resistant mice. Gessner A; Blum H; Röllinghoff M Immunobiology; 1993 Dec; 189(5):419-35. PubMed ID: 8125519 [TBL] [Abstract][Full Text] [Related]
8. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis. Zadeh-Vakili A; Taheri T; Taslimi Y; Doustdari F; Salmanian AH; Rafati S Vaccine; 2004 May; 22(15-16):1930-40. PubMed ID: 15121305 [TBL] [Abstract][Full Text] [Related]
9. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis. Iborra S; Soto M; Carrión J; Alonso C; Requena JM Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433 [TBL] [Abstract][Full Text] [Related]
10. Acute cysticercosis favours rapid and more severe lesions caused by Leishmania major and Leishmania mexicana infection, a role for alternatively activated macrophages. Rodríguez-Sosa M; Rivera-Montoya I; Espinoza A; Romero-Grijalva M; López-Flores R; González J; Terrazas LI Cell Immunol; 2006 Aug; 242(2):61-71. PubMed ID: 17118349 [TBL] [Abstract][Full Text] [Related]
11. Distinct immunological states in murine cutaneous leishmaniasis by immunising with different amounts of antigen: the generation of beneficial, potentially harmful, harmful and potentially extremely harmful states. Bretscher PA; Ogunremi O; Menon JN Behring Inst Mitt; 1997 Feb; (98):153-9. PubMed ID: 9382736 [TBL] [Abstract][Full Text] [Related]
12. IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis. Scott P J Immunol; 1991 Nov; 147(9):3149-55. PubMed ID: 1833466 [TBL] [Abstract][Full Text] [Related]
13. Functional plasticity of the LACK-reactive Vbeta4-Valpha8 CD4(+) T cells normally producing the early IL-4 instructing Th2 cell development and susceptibility to Leishmania major in BALB / c mice. Maillard I; Launois P; Himmelrich H; Acha-Orbea H; Diggelmann H; Locksley RM; Louis JA Eur J Immunol; 2001 Apr; 31(4):1288-96. PubMed ID: 11298356 [TBL] [Abstract][Full Text] [Related]
14. IL-1 signalling is dispensable for protective immunity in Leishmania-resistant mice. Kautz-Neu K; Kostka SL; Dinges S; Iwakura Y; Udey MC; von Stebut E Exp Dermatol; 2011 Jan; 20(1):76-8. PubMed ID: 20955202 [TBL] [Abstract][Full Text] [Related]
15. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile. Skeiky YA; Kennedy M; Kaufman D; Borges MM; Guderian JA; Scholler JK; Ovendale PJ; Picha KS; Morrissey PJ; Grabstein KH; Campos-Neto A; Reed SG J Immunol; 1998 Dec; 161(11):6171-9. PubMed ID: 9834103 [TBL] [Abstract][Full Text] [Related]
17. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Mattner F; Magram J; Ferrante J; Launois P; Di Padova K; Behin R; Gately MK; Louis JA; Alber G Eur J Immunol; 1996 Jul; 26(7):1553-9. PubMed ID: 8766560 [TBL] [Abstract][Full Text] [Related]
18. Leishmania major: targeting IL-4 in successful immunomodulation of murine infection. Wakil AE; Wang ZE; Locksley RM Exp Parasitol; 1996 Nov; 84(2):214-22. PubMed ID: 8932771 [TBL] [Abstract][Full Text] [Related]
19. Interleukin 1alpha activity of peritoneal and bone marrow macrophages infected with Leishmania major and Leishmania donovani in vitro. Bersudsky M; Apte RN; El-On J Exp Parasitol; 2000 Mar; 94(3):150-7. PubMed ID: 10831379 [TBL] [Abstract][Full Text] [Related]
20. The regulation of immunity to Leishmania major. Reiner SL; Locksley RM Annu Rev Immunol; 1995; 13():151-77. PubMed ID: 7612219 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]